Nektar Therapeutics (NASDAQ:NKTR) announced today that it has entered into a new clinical collaboration with Takeda Pharmaceutical Company Limited to evaluate Nektar's investigational medicine,...
Nektar Therapeutics (Nasdaq: NKTR) today announced that it is presenting new preclinical data for its immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting...
Nektar Therapeutics (Nasdaq: NKTR) today announced that it has initiated dosing patients in the Phase 1/2 REVEAL clinical study evaluating the efficacy and safety of the combination of...